-
Mashup Score: 13
Mammoth’s proprietary ultracompact CRISPR-based gene editing platform and Regeneron’s proprietary delivery technologies set to advance in vivo programs in multiple tissue and cell types Mammoth to receive $100 million total upfront payment and equity investment from Regeneron at signing TARRYTOWN,
Source: investor.regeneron.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 13
Oral presentation will feature new data for investigational REGN7075, an EGFRxCD28 costimulatory bispecific with the potential to enhance the treatment of certain advanced solid tumors in combination with Libtayo ® (cemiplimab-rwlc) 17 presentations to highlight Regeneron ‘s investigational
Source: investor.regeneron.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 19Praluent® (alirocumab) Injection Receives FDA Approval to Treat Children with Genetic Form of High Cholesterol | Regeneron Pharmaceuticals Inc. - 1 month(s) ago
Approval extends treatment of Praluent to children aged 8 and older with heterozygous familial hypercholesterolemia (HeFH) TARRYTOWN, N.Y. , March 11, 2024 (GLOBE NEWSWIRE) — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced the U.S. Food & Drug Administration (FDA) has extended the
Source: investor.regeneron.comCategories: General Medicine News, Cardiology News and JournTweet
-
Mashup Score: 3Regeneron Provides Update on Biologics License Application for Odronextamab | Regeneron Pharmaceuticals Inc. - 1 month(s) ago
TARRYTOWN, N.Y. , March 25, 2024 (GLOBE NEWSWIRE) — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has issued Complete Response Letters (CRLs) for the Biologics License Application (BLA) for odronextamab in relapsed/refractory (R/R)
Source: investor.regeneron.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 3Regeneron Provides Update on Biologics License Application for Odronextamab | Regeneron Pharmaceuticals Inc. - 1 month(s) ago
TARRYTOWN, N.Y. , March 25, 2024 (GLOBE NEWSWIRE) — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has issued Complete Response Letters (CRLs) for the Biologics License Application (BLA) for odronextamab in relapsed/refractory (R/R)
Source: investor.regeneron.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 30
NOTUS trial met its primary endpoint with overwhelming efficacy, showing Dupixent significantly reduced exacerbations by 34% compared to placebo in patients with moderate-to-severe COPD with evidence of type 2 inflammation (i.e., blood eosinophils ≥300 cells per μL), confirming results from the
Source: investor.regeneron.comCategories: General Medicine News, PayerTweet-
#BREAKING: Our mission is to always push the boundaries of science to help people with serious diseases. And with @Sanofi, we’re doing just that for those living with moderate-to-severe #COPD. Read more about today’s news and what it may mean for patients: https://t.co/7ew9lUhD7p https://t.co/GPomSDAHK0
-
-
Mashup Score: 24
Regeneron has sponsored ISEF – the world’s largest high school science and engineering competition, and a program of Society for Science (Society) – since 2019 Each year, over 175,000 students participate in the Society’s affiliated high school science fairs around the world to earn the right to
Source: investor.regeneron.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 2
Approval based on the pivotal PULSAR and PHOTON trials in which EYLEA ® HD demonstrated clinically equivalent vision gains to EYLEA (aflibercept) Injection 2 mg that were maintained with fewer injections First and only treatment approved in wAMD and DME for immediate dosing at 8-week and up to
Source: investor.regeneron.comCategories: Healthcare Professionals, Latest HeadlinesTweet
-
Mashup Score: 1
TARRYTOWN, N.Y. , Aug. 17, 2023 (GLOBE NEWSWIRE) — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the European Medicines Agency (EMA) has accepted for review the Marketing Authorization Application (MAA) for odronextamab to treat adult patients with relapsed/refractory (R/R)
Source: investor.regeneron.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
🚨 NEWS 🚨 @EMA_News to review a marketing authorization application for CD20 × CD3, a bispecific antibody, for adults with R/R #FL or #DLBCL who progress after ≥2 prior systemic therapies, following supporting data from ELM-1 and ELM-2. https://t.co/NN7cnVSt2L. #lymsm #mednews https://t.co/pIuQuHfFDc
-
We’re announcing a new collaboration with @mammothbiosci that pairs their ultracompact CRISPR editing systems with our innovative delivery technologies, expanding our targeted gene editing abilities across multiple tissue and cell types. Learn more: https://t.co/K7vFZyvMk3